Endpoints1h ago1 min read

Using gray-market versions of Lilly’s triple-G leads to relatively poor weight loss, study finds

Eli Lilly’s triple agonist retatrutide appears to be the most effective obesity drug to have reached late-stage trials, with weight loss of up to 25% in Phase 3. This has led growing ...

Aug 20, 2026read at Endpoints ↗

August 20, 2026 11:12 AM EDT PharmaHealth TechGLP-1 drugs Using gray-market versions of Lilly’s triple-G leads to relatively poor weight loss, study finds Elizabeth Cairns Senior biopharma journalist Eli Lilly’s triple agonist retatrutide appears to be the most effective obesity drug to have reached late-stage trials, with weight loss of … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

source

Reporting by Endpoints.

read at Endpoints ↗

85 words · retrieved 52m ago

sharex / twitter linkedin

Using gray-market versions of Lilly’s triple-G leads to relatively poor weight loss, study finds

comments(0)

Using gray-market versions of Lilly’s triple-G leads to relatively poor weight loss, study finds

comments(0)